#AS­CO21: Take­da flesh­es out case for oral EGFR drug with fol­low-up piv­otal da­ta in non-small cell lung can­cer

Take­da is look­ing to carve out a ma­jor niche in non-small cell lung can­cer with an oral TKI in­hibitor tar­get­ing a rare but des­per­ate pa­tient pop­u­la­tion. Now, with the FDA al­ready check­ing its math, Take­da is un­veil­ing up­dat­ed da­ta adding even more heft to that drug’s case.

Take­da’s mobo­cer­tinib post­ed a me­di­an OS of 24 months at a 14-month fol­low-up in pa­tients with EGFR Ex­on20 in­ser­tion mu­ta­tion-pos­i­tive, metasta­t­ic NSCLC who re­ceived pri­or plat­inum-based chemother­a­py, ac­cord­ing to fol­low-up da­ta from a Phase I/II study set to be pre­sent­ed at AS­CO in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER